Please check your internet connection and try again.
## Clobazam (Oral)
### Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties, used as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS).
### Primary Indications
* Adjunctive treatment of seizures in patients with Lennox-Gastaut syndrome (LGS).
### Adult Dosing
* **Initiation:** 5 mg twice daily.
* **Titration:** Increase dose every 3 days as tolerated. Maximum initial titration dose is 10 mg twice daily.
* **Maintenance:** Usual maintenance dose is 10-20 mg twice daily.
* **Maximum Daily Dose:** 20 mg twice daily (40 mg/day).
### Pediatric Dosing (LGS)
* **Initiation (2 to less than 10 years):** 2.5 mg twice daily.
* **Initiation (10 years or older):** 5 mg twice daily.
* **Titration:** Increase dose every 3 days as tolerated.
* **2 to less than 10 years:** Maximum initial titration dose is 5 mg twice daily.
* **10 years or older:** Maximum initial titration dose is 10 mg twice daily.
* **Maintenance:**
* **2 to less than 10 years:** Usual maintenance dose is 5-10 mg twice daily. Maximum daily dose is 20 mg twice daily (40 mg/day).
* **10 years or older:** Usual maintenance dose is 10-20 mg twice daily. Maximum daily dose is 20 mg twice daily (40 mg/day).
### Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dosing adjustments are established, but lower doses may be warranted.
* **Renal Impairment:** Use with caution. No specific dosing adjustments are established.
### Contraindications
* Hypersensitivity to clobazam or other benzodiazepines.
* Severe hepatic impairment.
### Adverse Effects
* **Common:** Somnolence, sedation, drooling, constipation, decreased appetite, ataxia, vomiting, fatigue, irritability, upper respiratory tract infection.
* **Serious:** Suicidal behavior and ideation, severe somnolence, withdrawal symptoms (including seizures), respiratory depression, abuse and dependence.
### Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other benzodiazepines, sedating antihistamines):** Increased risk of profound sedation, respiratory depression, coma, and death.
* **CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole, clarithromycin):** May increase clobazam concentrations.
* **CYP3A4 Inducers (e.g., rifampin, carbamazepine, phenytoin):** May decrease clobazam concentrations.
* **Strong CYP2C19 Inhibitors (e.g., fluconazole):** May increase clobazam concentrations.
### Monitoring
* Monitor for signs of sedation, respiratory depression, and suicidal behavior/ideation.
* Assess for withdrawal symptoms upon discontinuation.
* Evaluate effectiveness in seizure control.
### Clinical Pearls
* Clobazam should be used as adjunctive therapy and not as monotherapy for LGS seizures.
* Due to potential for dose-related adverse effects, slow titration is recommended.
* Patients and caregivers should be advised of the risks of somnolence and to avoid activities requiring mental alertness until the effects are known.
* Abrupt discontinuation can lead to withdrawal symptoms. Tapering of the dose is recommended.
* Clobazam is metabolized by CYP2C19 and CYP3A4.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant guidelines before making clinical decisions. This summary does not replace professional judgment.*
